Full-Time

Executive Assistant

C-Suite, Medtech

CVRx

CVRx

201-500 employees

Neuromodulation device for heart failure treatment

Compensation Overview

$80k - $90k/yr

No H1B Sponsorship

Brooklyn Park, MN, USA

Hybrid

Four days on-site and one work-from-home day per week are required.

Bachelor's

Category
Administrative & Executive Assistance (2)
,

Get referred to CVRx

See people who can refer or advise you

Requirements
  • A Bachelor's degree or equivalent work experience is required.
  • A minimum of 8 years of executive administrative support experience, including support of senior leaders, is required.
  • Experience managing highly confidential information with professionalism, discretion, and sound judgment is required.
  • Exceptional interpersonal, verbal, and written communication skills, with the ability to adapt communication style to diverse audiences, are required.
  • The candidate must be able to build collaborative working relationships and partner across executive teams, administrative teams, and business functions.
  • The candidate must be able to anticipate executive needs, exercise sound judgment, proactively solve problems, and independently develop practical, cost-effective solutions with minimal supervision.
  • Exceptional organizational, planning, prioritization, and follow-through skills are required, including the ability to manage competing priorities accurately and with attention to detail.
  • Emotional intelligence, professionalism, adaptability, and resilience in a fast-paced environment are required.
  • Expert-level proficiency with Microsoft 365 applications and other business software is required, along with the ability to learn and use emerging technologies and digital tools.
  • The candidate must be action-oriented, able to prioritize, and willing to remain flexible based on business needs.
  • The candidate must be open and flexible with availability for projects and meetings as necessary.
  • The candidate must be able to travel approximately 5% for United States-based travel.
  • The candidate must be able to lift approximately 15–20 pounds.
  • Candidates must be legally authorized to work in the United States without current or future sponsorship.
Responsibilities
  • Serve as the primary administrative point of contact for the Chief Revenue Officer and assigned executives, functional areas, and organizational workstreams.
  • Manage communications, inquiries, requests, and administrative priorities with professionalism and discretion.
  • Build and maintain relationships with internal and external stakeholders while representing the assigned executive and CVRx confidentially and professionally.
  • Prioritize, route, and respond to communications and requests using independent judgment, ensuring timely follow-up and resolution.
  • Handle confidential business and company information with discretion and sound judgment.
  • Draft, edit, summarize, and distribute professional correspondence, presentations, and other communications.
  • Manage executive calendars, meeting priorities, scheduling conflicts, and recurring meeting cadence.
  • Coordinate executive meeting logistics, including attendees, rooms, Microsoft Teams links, agendas, pre-read materials, catering, and follow-up tracking where appropriate.
  • Schedule and coordinate international and domestic business travel, including itineraries, agendas, transportation, lodging, and meeting accommodations.
  • Coordinate administrative logistics for organizational workstreams, including meetings, events, vendors, purchasing, invoice processing, catering, and related administrative tasks.
  • Prepare complex Concur expense reports, open and sort mail, file, create documents and presentations, and perform other general administrative functions.
  • Provide secondary backup support for designated executives or functions during leave, transitions, urgent coverage needs, or workload spikes.
  • Collaborate with other Executive Assistants to coordinate coverage, share knowledge, and maintain standardized administrative practices and documentation.
  • Complete special projects by establishing priorities, coordinating resources, monitoring progress, solving problems, and adjusting plans.
  • Perform other job-related duties as assigned.
Desired Qualifications
  • Experience supporting one or more remote C-level executives in a fast-growing public company.
  • Experience supporting senior executives in Commercial Sales organizations.
  • Experience coordinating executive-level meetings, conferences, on-site events, or cross-functional initiatives.
  • Ability to identify process improvement opportunities and recommend practical, scalable solutions.
  • Experience or exposure to continuous improvement methodologies.

CVRx develops BAROSTIM NEO, a neuromodulation therapy for heart failure. The device delivers electrical stimuli to baroreceptors in the cardiovascular system to modulate nerve activity and support blood pressure regulation, aiming to improve heart function in patients who struggle with fatigue, shortness of breath, and fluid retention. The system works through an implanted or wearable neuromodulation device that interacts with the body's nerve signals to influence cardiovascular control. CVRx differentiates itself by offering a focused solution for heart failure that combines the device with provider-focused support programs to facilitate patient access and reimbursement, working with hospitals and clinics to implement therapy. The company's goal is to improve patient outcomes for heart failure and expand the adoption of BAROSTIM THERAPY by helping healthcare providers treat more patients effectively.

Company Size

201-500

Company Stage

IPO

Headquarters

Minneapolis, Minnesota

Founded

2001

Get referred to CVRx

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Second-quarter 2026 revenue reached $15.7 million, up 16%, with 87% gross margin.
  • Traditional Medicare paid approximately 96% of claims, improving conversion economics in 2026.
  • Humana approval rates exceeded 90%, supporting Barostim adoption in a major payer channel.

What critics are saying

  • August 2026 DOJ CID targets sales, marketing, kickbacks, and false claims allegations.
  • August 2026 guidance cut to $58M-$60M exposed salesforce turnover and reimbursement fragility.
  • A 59% August 7 stock crash and CRO firing signal execution collapse or litigation spiral.

What makes CVRx unique

  • Barostim is FDA-approved, first neuromodulation therapy for heart failure symptoms.
  • January 2026 Category I CPT codes normalized billing and strengthened reimbursement infrastructure.
  • Humana’s May 2026 Medicare Advantage policy expanded access across 5.2 million members.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Stock Options

Company Equity

Paid Holidays

Parental Leave

Flexible Work Hours

Remote Work Options

Training Programs

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-1%

2 year growth

-1%
Yahoo Finance
Aug 13th, 2026
CVRx lowers 2026 guidance despite 16% Q2 growth to $15.7M

CVRx reported second-quarter 2026 revenue of $15.7 million, up 16% year-over-year, with an 87% gross margin. However, the medical device company lowered its full-year revenue guidance due to anticipated weakness in the second half of the year. CEO Kevin Hykes attributed the revised outlook to challenges with sales force integration. The company maintained 56 US sales territories, but approximately 60% of quota-carrying territory managers joined within the past 18 months. This rapid hiring pace has strained onboarding and training processes. The company cited high turnover rates, slower productivity ramp-up for new hires, and concentration of new employees in specific regions as primary factors affecting performance. Despite these challenges, regions with stable leadership and experienced teams are achieving strong double-digit growth, suggesting the company's strategy remains sound where properly executed.

GlobeNewswire
Aug 13th, 2026
HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, encourages CVRx Inc. (CVRX) Investors with substantial losses to Contact firm: investigating potential securities fraud following 59% stock drop.

HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, encourages CVRx Inc. (CVRX) Investors with substantial losses to Contact firm: investigating potential securities fraud following 59% stock drop. SAN FRANCISCO, Aug. 13, 2026 (GLOBE NEWSWIRE) - Hagens Berman, a national shareholder rights litigation firm, announces it has opened an investigation into CVRx Inc. (NASDAQ: CVRX) regarding potential violations of federal securities laws. The investigation follows disclosures of a U.S. Department of Justice Civil Investigative Demand ("CID"), severe cuts to revenue guidance, commercial sales force disruption, and the sudden termination of the company's Chief Revenue Officer. CVRx Inc. (NASDAQ: CVRX) Investors: Investors who suffered substantial losses are encouraged to submit your losses now to evaluate their legal rights and recovery options. * Visit: www.hbsslaw.com/cases/cvrx * Contact Partner Reed Kathrein: 844-916-0895 | [email protected] INVESTIGATION OVERVIEW: CVRx Inc. (NASDAQ: CVRX) "We are investigating whether there is a direct connection between the Department of Justice CID and the immediate termination of the Chief Revenue Officer,..." CVRx's sole commercial product is Barostim, an FDA-approved implantable neuromodulation device designed to improve symptoms for patients suffering from heart failure. Historically, CVRx assured investors that its growth strategy was anchored by a complete sales force transformation and high approval rates from Medicare Advantage payers. CVRx repeatedly highlighted a "$10.5 billion market opportunity" with less than 1% penetration, reassuring the market earlier this year that its sales force transformation was "largely complete." However, after market close on August 6, 2026, CVRx disclosed a series of severe operational and legal headwinds: * DOJ Civil Investigative Demand (CID): On May 14, 2026, CVRx received a CID from the U.S. Department of Justice investigating whether the company caused the submission of false claims to government health programs by improperly marketing Barostim, paying kickbacks to healthcare providers, or submitting false information. * Sales Force Deterioration & Guidance Cut: CVRx significantly cut its 2026 revenue expectations and revealed serious problems with its salesforce - sequentially flat growth in sales territories, turnover, and strained onboarding and training. * Medicare Advantage Approval Collapse: CVRx revealed that its primary Medicare Advantage payer - which historically approved 80% of prior authorizations within 30 days - increased initial denials and reduced 30-day approvals to just 25%. In response to these revelations, CVRx's stock price cratered 59% on August 7, 2026. Three days later, on August 10, 2026, CVRx abruptly terminated its Chief Revenue Officer (CRO), Robert John. FOCUS OF THE HAGENS BERMAN INVESTIGATION "We are investigating whether there is a direct connection between the Department of Justice CID and the immediate termination of the Chief Revenue Officer, as well as whether CVRx may have misled investors regarding the true state of its commercial sales force and Medicare Advantage reimbursement rates," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation. WHAT CVRx (CVRX) INVESTORS & WHISTLEBLOWERS CAN DO * Investors: If you invested in CVRx, Inc. (NASDAQ: CVRX) and suffered significant financial losses, you can submit your losses now. * Whistleblowers: Persons with non-public information regarding CVRx should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected]. About Hagens Berman Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Yahoo Finance
Aug 7th, 2026
CVRx reports $15.7M revenue (+16% YoY) but cuts 2026 guidance to $58-60M amid sales execution challenges

CVRx Inc reported Q2 2026 revenue of $15.7 million, up 16% year-over-year, with US revenue climbing 21% to $14.8 million. However, European revenue fell 31% to $900,000. The medical device company achieved an 87% gross margin, improving from 84% previously. Despite positive metrics, CVRx lowered its full-year 2026 revenue guidance to between $58 million and $60 million due to sales execution challenges. The company cited high sales force turnover, with roughly 60% of territory managers having joined within the last 18 months, straining training processes. Reimbursement showed improvement, with Medicare Advantage prior authorisation approval rates rising to 60% from 44% in 2025. Traditional Medicare claims are now paid at approximately 96% across all administrative contractors. CVRx ended the quarter with $64.6 million in cash. The company reported a net loss of $14 million, or $0.53 per share.

Yahoo Finance
Jun 29th, 2026
CVRx shares surge 11.6% on strong Q1 results beating estimates

CVRx shares rose 11.6% to close at $5.86, driven by investor optimism following strong first-quarter 2026 results. The medical device company posted a loss of 50 cents per share on revenues of $14.8 million, with both figures exceeding Zacks Consensus Estimates. For the upcoming quarter, CVRx is expected to report a loss of $0.52 per share on revenues of $15.64 million, representing year-over-year improvements of 8.8% and 15.1%, respectively. However, the consensus earnings estimate has remained unchanged over the past 30 days. The stock currently carries a Zacks Rank of Hold. CVRx is part of the medical instruments industry, alongside companies like Steris, which gained 2.4% in the last session.

The Jewish Link
May 20th, 2026
CVRx to present at the William Blair 46th Annual Growth Stock Conference.

CVRx to present at the William Blair 46th Annual Growth Stock Conference. GlobeNewswire | CVRx, Inc. Today at 1:30pm PDT MINNEAPOLIS, May 20, 2026 (GLOBE NEWSWIRE) - CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that the management team will present at the William Blair 46th Annual Growth Stock Conference in Chicago on Tuesday, June 2, 2026. The Company's presentation will begin at 10:40 a.m. (CT). A live webcast of the event can be found at ir.cvrx.com. An archived version of the presentation will be available following the live event and can be accessed at the same location for a limited time. About CVRx, Inc. CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim(TM) is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com. Investor Contact: Mark Klausner or Mike Vallie ICR Healthcare 443-213-0501 [email protected] Media Contact: Emily Meyers CVRx, Inc. 763-416-2853 [email protected] This is a paid placement. For further inquiries, please contact GlobeNewswire directly.